Patients experienced additional partial seizure control when TRILEPTAL therapy was added to 1 or 2 other antiepileptic drugs (AEDs) Reduction in frequency of partial seizures with TRILEPTAL adjunctive therapy1,2

Adult Efficacy Pediatric Efficacy First-line Use TRILEPTAL vs CBZ

	Clear dose response across effective dosage range of 600 to 2400 mg/day1,2
	Prior to the addition of TRILEPTAL, patients were taking up to 3 AEDs, including1,2 —Carbamazepine (75%) —Valproate (25%) —Phenytoin (21%) —Lamotrigine (13%)

Study limitations

36% of patients in the 1200-mg/day group and 67% in the 2400-mg/day group discontinued therapy due to adverse events (central nervous system [CNS]- and dose-related)2 — No dosage adjustments were permitted for TRILEPTAL or the concomitant AEDs2 — A rapid forced-titration schedule was required by the study protocol during the first 3 weeks of therapy2

References:

1.		Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
2.		Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41:1597-1607.